Compare · ARGX vs IOVA
ARGX vs IOVA
Side-by-side comparison of argenx SE (ARGX) and Iovance Biotherapeutics Inc. (IOVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IOVA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 29.3x IOVA ($1.89B).
- Over the past year, ARGX is up 52.8% and IOVA is up 91.4% - IOVA leads by 38.6 points.
- IOVA has been more active in the news (7 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 20 for IOVA).
- Company
- argenx SE
- Iovance Biotherapeutics Inc.
- Price
- -
- -
- Market cap
- $55.32B
- $1.89B
- 1M return
- +10.56%
- +2.55%
- 1Y return
- +52.81%
- +91.38%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 20
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Iovance Biotherapeutics Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest IOVA
- Interim CEO & General Counsel Vogt Frederick G converted options into 41,668 shares and covered exercise/tax liability with 17,701 shares, increasing direct ownership by 5% to 553,505 units (SEC Form 4) (withholding obligation)
- Chief Regulatory Officer Puri Raj K. covered exercise/tax liability with 2,508 shares and converted options into 5,469 shares, increasing direct ownership by 1% to 242,191 units (SEC Form 4) (tax liability)
- Chief Medical Officer Graf Finckenstein Friedrich covered exercise/tax liability with 4,473 shares and converted options into 8,790 shares, increasing direct ownership by 3% to 136,274 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Bilinsky Igor converted options into 8,790 shares and covered exercise/tax liability with 4,473 shares, increasing direct ownership by 3% to 130,083 units (SEC Form 4) (tax withholding)
- Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics to Present at Upcoming Conference
- Chief Commercial Officer Kirby Daniel Gordon converted options into 10,000 shares and covered exercise/tax liability with 2,435 shares, increasing direct ownership by 5% to 146,946 units (SEC Form 4) (tax withholding)
- SEC Form SCHEDULE 13G filed by Iovance Biotherapeutics Inc.
- Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits